RxDoctor Payments Data

David Grinsfelder, MD

Internal Medicine · Dallas, TXNPI 1568966174

Payments from drug & device makers

$304in general payments, 2019–2025

Across 12 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$68
  • GSK$66
  • Abiomed$54
  • Inari Medical, Inc.$42
  • Exact Sciences$28
  • Echosens North America, Inc.$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$304 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$365,610
Medicare patients
661
Services billed
8,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$137,219
MounjaroTirzepatide74$87,320
JardianceEmpagliflozin64$53,744
OzempicSemaglutide51$49,985
BiktarvyBictegrav/Emtricit/Tenofov Ala11$42,917
Synjardy XrEmpagliflozin/Metformin Hcl61$36,981
XareltoRivaroxaban41$36,514
JanuviaSitagliptin Phosphate24$26,252
GemtesaVibegron26$23,537
MyrbetriqMirabegron26$16,983
TradjentaLinagliptin26$16,627
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,413
JanumetSitagliptin Phos/Metformin Hcl11$13,442
Janumet XrSitagliptin Phos/Metformin Hcl20$13,321
FarxigaDapagliflozin Propanediol15$9,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$66$22,57332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →